The Cartel Indictment of AI Safety: Seven Days That Turned Coordination into a Legal Liability
On September 18, 2026, a docket number quietly appeared in the Northern District of California: 3:26-cv-10693. The case, Buist et al. v. Anthropic PBC et al., was filed by four paying subscribers—not by the Department of Justice, not by a consumer advocacy group, but by four individuals who believe they have identified the most consequential cartel of the decade. Their claim is simple and devastating: when Anthropic, OpenAI, SpaceXAI, and Google coordinate to slow the development of frontier AI, they are restricting output. Under Section 1 of the Sherman Act, the rationale for restricting output does not matter. Safety is not an exemption. Intent is not a defense. And the same-day public endorsements that followed Dario Amodei's September 12 essay, "We Must Pace the Frontier," look like evidence of agreement.
I spent my first bull market auditing smart contracts that were supposed to change the world but were really just exit strategies. That experience taught me that technology without ethical financial frameworks is destined to collapse. But this lawsuit is not about ethics. It is about market structure. And in a single week, the institutional architecture that made AI safety coordination possible collapsed under the weight of antitrust law, executive hostility, and a blocked legislative waiver.
To understand how we got here, we have to reconstruct the week. On September 12, Amodei published a widely shared essay arguing that frontier laboratories should voluntarily decelerate—pacing capability gains in exchange for safety review. Within hours, Sam Altman, Elon Musk, and Demis Hassabis offered public endorsements. By September 15, OpenAI's Chris Lehane had confirmed to TechCrunch that the major labs had been coordinating on safety protocols for weeks. The coordination was real, and it was open. That openness proved to be a legal vulnerability.
On September 15, the legislative route closed. Senator Josh Hawley, backed by Senator Ted Cruz, blocked a national-security antitrust exemption from the NDAA manager's package. Hawley's message was blunt: "No antitrust exemptions for AI. Not a chance." The exemption was the narrow legal window that would have allowed competitors to coordinate on safety standards without triggering Sherman Act exposure. Amodei had identified this window as essential. Without it, any agreement among labs about capability limits is prima facie illegal.
On September 18, the antitrust suit landed. On September 19, President Trump announced an AI Force and a new AI Czar, dismissed safety as a "hoax," and floated renaming AI "Superior Intelligence" or "Extreme Intelligence." No appointee, no implementation details, no policy framework. Just a signal that the executive branch no longer sees safety as a legitimate goal. David Sacks had resigned in March after hitting the 130-day special government employee limit, and the replacement has not been named. The gap is not administrative. It is ideological.
Those three events—a lawsuit, a dismissal, a blockade—are often treated separately. They are not. They are three vectors aimed at the same target. And the target is the governance assumption that frontier labs can coordinate on safety without breaking the law, losing political cover, or exposing themselves to existential litigation.
The week in three acts is worth parsing carefully, because the order matters. The legislative blockade came first, though it is tempting to start with the lawsuit. The Hawley-Cruz maneuver quietly eliminated the legal mechanism that would have made coordination lawful. Then the lawsuit weaponized the coordination that had already happened. Then the executive branch removed any remaining political cover. Each act made the next one more damaging. If the exemption had passed, the labs could have pointed to a statutory safe harbor. If the lawsuit had been filed first, the labs might have paused their coordination and avoided further evidence. If the executive branch had stayed neutral, the industry could have presented its safety work as a patriotic commitment. Instead, the sequence of events created a perfect legal storm. The labs were simultaneously accused of acting illegally, stripped of the mechanism that would have made their actions legal, and condemned by the only branch that could have argued they were acting in the public interest.
Let me start with the law, because this is where the technical details matter. Section 1 of the Sherman Act prohibits any contract, combination, or conspiracy that unreasonably restrains trade. The Supreme Court has long held that an explicit agreement is not necessary; a "conscious commitment to a common scheme" can be inferred from conduct. The plaintiffs in Buist will likely argue that the public endorsements on September 12, combined with Lehane's confirmation of weeks of coordination, establish that common scheme. The fact that the restraint is framed as a voluntary safety measure does not change the output-restriction analysis. If competitors agree to lower speed or capability, the product they sell is, in some meaningful sense, reduced. Consumers—whether they are enterprise clients buying model access or ordinary users relying on free tiers—are receiving less than they would have received absent the agreement.
The defense will be more sophisticated. They will argue that safety output is not the same as commercial output; that a slower, safer model is a different product, not a restricted one; and that no individual lab had a legal obligation to pursue maximum capability. They will point to the rule of reason, which asks whether a restraint has procompetitive or anticompetitive effects. They will argue that preventing catastrophic accidents is the ultimate procompetitive benefit. That argument may work with a sympathetic judge. It will not work in the court of public opinion. "Safety cartel" is a phrase that will be repeated until it becomes a meme. And in an industry already suspected of regulatory capture, the optics are terrible.
The deeper problem is that coordination has a double nature. To be effective for safety, coordination must be broad and consistent. To be legal under antitrust law, coordination must be narrow and unilateral. A lab can slow its own development because it wants to. It cannot slow its development because it asked its competitors to do the same. The difference is one of evidence, not substance. This is why Amodei's framework was always going to be vulnerable: it requires the appearance of agreement to be credible, and that appearance is now evidence of a cartel.
Follow the money, not the noise. The lawsuit is not being bankrolled by a consumer protection group. The plaintiffs are four paying subscribers, likely individuals with access to some subscription product and a strong opinion about AI policy. They do not need to win on the merits to destroy the coordination thesis. The cost of defending the case, the discovery process, the depositions of the founders, the internal emails about safety coordination—all of that will be disclosed. Even if the case is dismissed on a motion to dismiss, the discovery phase alone will reveal the mechanics of how the labs actually coordinated. And that discovery will likely produce a second lawsuit, this time from a more capable plaintiff.
Now add the executive branch. Trump's September 19 announcement is not a policy document; it is a signal to capital. The "AI Force" evokes a mandate for growth, not oversight. The reference to "Superior Intelligence" is rhetorical, but the direction is clear: the federal government will not be a brake on frontier AI. It will be an accelerator. For a lab trying to justify safety coordination to its board, that changes the calculus. The political cover that made coordination possible—the assumption that the government wanted the labs to be careful—is gone. In its place is a political environment that treats safety as a hoax and coordination as a job-destroying conspiracy.
What does that do to the capital markets? Let me be specific. In the 2024 ETF cycle, I watched institutional capital flow into a small set of large-cap tokens and AI-linked equities. The macro dynamic was simple: low interest rates, passive allocation, and a regulatory environment that favored custody over innovation. The same dynamic is now emerging around frontier AI. But institutional investors are not buying safety. They are buying downside protection. A lab with a credible safety brand can charge a premium for its services. A lab that becomes a defendant in a Sherman Act case cannot. The reported IPO deliberations at Anthropic are therefore happening at the worst possible time. An initial public offering under an antitrust cloud is not an exit; it is a liability event. OpenAI's no-IPO stance looks less ideological and more rational by comparison. You cannot be the target of a cartel suit and simultaneously sell the market on a governance story that depends on quiet coordination.
The legislative blockade completes the trap. Senator Hawley's move was not just procedural. It was a message to the entire AI sector: if you want safety rules, you will have to pass them in public, through the normal legislative process, and you will have to accept that they apply to you. No more backroom pacts. No more industry self-regulation masquerading as public policy. The Cruz-Klobuchar-Thune duty-of-care bill remains on the table, but without the antitrust exemption, it is a shell. The bill would impose duties, but it would not authorize competitors to coordinate on how to satisfy those duties. A duty-of-care regime without a safe harbor for collective action is a trap: labs are simultaneously required to be careful and forbidden to coordinate on what careful means.
This is the liability vacuum. The Amodei pacing framework proposed voluntary deceleration as a governance model. The antitrust suit says voluntary deceleration, if coordinated, is illegal. The executive branch says deceleration is unnecessary. Congress has blocked the mechanism that would have made it legal. No actor has the authority or the will to set the terms. This is not a policy disagreement. It is a structural breakdown.
Why should anyone in crypto care? Because the same pattern will be applied to token networks. I have seen this before. In 2017, I audited seven utility tokens and found that their governance structures were designed to fail—the founding teams controlled liquidity, the community had no power, and the "decentralized decision-making" was a compliance shield. The AI safety coordination regime has the same flaw: it asks competitors to do something that looks illegal, then provides no legal mechanism for doing it legally. The result is either a cartel or a vacuum. In crypto, we called it "regulation by enforcement." In AI, it is now "governance by litigation."
The FINRA-style safety body that Anthropic, Google, and reportedly OpenAI have been building continues to operate. But what can it actually do? It can issue reports. It can share best practices. It cannot issue binding rules, because any binding rule that limits capability would be output-restricting. It cannot even issue non-binding recommendations, because the act of jointly issuing recommendations could be used as evidence of a conspiracy. The body itself has become a legal liability. A regulator without authority is just a mailing list. A safety body without authority is a honeypot for discovery.
This is the moment where my own experience tells me to look at process, not promises. In 2022, after watching leveraged protocols collapse, I retreated from public commentary for three months. When I returned, I argued that decentralized systems mirror individual psychological resilience: the real test is not whether a protocol survives a bull market, but whether it can survive a coordinated attack on its assumptions. The same is true for AI safety coordination. The labs assumed that the federal government would tolerate their coordination. That assumption died on September 19. They assumed that Congress would provide a safe harbor. That assumption died on September 15. They assumed that antitrust law would respect safety rationales. That assumption is now being tested in court.
The question is not whether the labs can continue to talk about safety. They can, and they will. The question is whether they can continue to coordinate on safety. My answer is no. Not because the safety work is unimportant, but because the legal reality has changed. The cost of coordination now exceeds the cost of unilateral action. That is a dangerous equilibrium for a technology that requires collective restraint. It is also a familiar equilibrium for anyone who has watched a commodity market become oversupplied after a cartel agreement collapses. Volatility is the tax on impatience. The industry will pay it.
Now the contrarian angle. The collapse of the coordination framework might be the best thing that has happened to AI safety in a decade. Consider: the only safety mechanism that can survive both antitrust scrutiny and political hostility is one that is unilateral, verifiable, and transparent. "We will slow down because we choose to" is legal. "We will slow down because we all agreed to" is not. That distinction forces labs to make their safety commitments individually auditable. Instead of relying on private assurances, the market will demand public evidence: red team reports, capability caps, third-party audits. The safety community loses the comfort of collusion and gains the discipline of verification.
This is exactly where blockchain and cryptography have an unexpected contribution. In my 2026 work on AI-crypto convergence, I have been designing frameworks for verifying AI-generated content on-chain. The same trustless verification mechanisms can be applied to safety claims. A lab could publish a signed commitment to a specific capability limit, then provide periodic evidence that the limit has not been exceeded. That is not a cartel; it is a public good. No agreement with competitors is required. No antitrust exemption is needed. The market can reward the lab for its restraint, and the regulator can penalize the lab for cheating. This is a better governance model than the one that died this week.
The conventional wisdom says the labs are doomed. I think the opposite. The labs that treat safety as a legal liability will abandon it as a coordination strategy. The labs that treat safety as an engineering discipline will build the tools to make it verifiable. The next wave of AI safety will not be negotiated behind closed doors. It will be encoded in smart contracts, disclosed in quarterly audits, and priced by the capital markets. That is the information gain I want readers to take from this analysis: the collapse of voluntary coordination is not the end of AI safety. It is the beginning of AI safety as a measurable, enforceable, and honest practice.
The question we should be asking is not whether Anthropic, OpenAI, SpaceXAI, and Google will survive the antitrust suit. They will. The question is whether any of them has the courage to publish a unilateral safety commitment that is genuinely verifiable. If they do, the lawsuit will be remembered as the moment the industry grew up. If they do not, then the coordination narrative was never about safety at all. It was about controlling the pace of change without taking responsibility for it. Follow the money, not the noise. The liability vacuum will be filled by someone—either the courts, or the engineers, or the shareholders. The only path that does not lead to collapse is the one where safety becomes a matter of public proof, not private pact. Volatility is the tax on impatience, and this industry has been impatient for a very long time.